The size of the European single-cell analysis market is forecasted to be worth USD 0.57 billion in 2022 and USD 1.21 billion by 2027, growing at a CAGR of 16.27% from 2022 to 2027.
Many biological experiments are performed with the assumption that all cells in a particular group are identical and homogenous. The single-cell analysis was introduced after the myth mentioned above was busted, and it became evident that cells within a group are heterogeneous. Individual cells of a population may differ vastly, and these differences bring a vast number of consequences to the health and functioning of the entire population.
New approaches to single-cell analysis aim to uncover the fundamental biological principles and ultimately lead to an improved and efficient disease detection system. The information collected may also prove invaluable in the treatment of diseases. Other applications of single-cell analysis include unlocking the gene-expression profiles between individual cells and discovering previously undetected subpopulations that escaped detection due to the mistake of taking averages of the entire cell population.
The single-cell analysis market is driven by factors such as the increased use of microfluidics in single-cell analysis instruments and the increasing interest in single-cell analysis research, as is evident from the number of conferences and meetings on the higher adoption of single-cell analysis. Additionally, growing consumer awareness about technological advancements in the medical field has led to a newfound demand for personalized medicine. Therefore, single-cell analysis is a vital research sector in customized medicine development and is also driven by the need.
Despite the positives outweighing the negatives, the growth rate is still hampered by the high costs of the instruments used in the said analysis. Even in financially abundant regions, the high costs of the devices put single-cell analysis beyond the reach of the majority of the population.
This research report on the Europe Single-Cell Analysis market has been segmented and sub-segmented into the following categories:
Geographically, the UK Single-cell analysis market is estimated to lead the European market during the forecast period. In the United Kingdom, organizations, including Cancer Research UK, Medical Research Council, The National Institute for Health Research, and Whales, have made a collective investment for more development and innovation of particular medicine in the country. Therefore, the advancements of single-cell analysis in the market are mainly observed in medicine and research.
On the other hand, the German single-cell analysis market is predicted to showcase the fastest CAGR from 2022 to 2027 due to increased research and development centers investments. In addition, the rise in the incidences of infectious diseases is also a factor propelling the market's demand.
KEY MARKET PLAYERS:
Companies playing a noteworthy role in the European single-cell analysis market profiled in this report are Merck KGaA, Becton, Dickinson and Company, Promega Corporation, Danaher Corporation, General ElectricCompany, Thermo Fisher Scientific, Miltenyi Biotec, Illumina, Bio-Rad Laboratories, Fluidigm Corporation, NanoString Technologies, Agilent Technologies, Abcam Plc, NuGEN Technologies Inc., LumaCyte, PluriSelect Life Science UG & Co. KG, Sysmex Partec, Bio-Techne Corporation, Promega Corporation, 10x Genomics, WaferGen Bio-systems, Bruker, and Fluxion Bioscience.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com